From Startup Anika Therapeutics
BEDFORD, Mass.–(BUSINESS WIRE)–Dec. 12, 2018–
Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic
and regenerative medicines company specializing in therapeutics based on
its proprietary hyaluronic
acid (“HA”) technology, today announced plans to showcase
its entire Orthobiologics franchise, including HYALOFAST,
at the upcoming ICRS Focus Meeting in Milan, Italy at the Humanitas
Research University. The ICRS is the main forum for international
collaboration in cartilaginous tissue research and joint preservation,
with 1300 active members from 65 countries.
HYALOFAST is a non-woven, single-step, off-the-shelf, biodegradable
HA-based scaffold for hyaline-like cartilage regeneration to treat
cartilage injuries and defects. HYALOFAST is commercially available in
approximately 15 countries and has been used to successfully treat more
than 15,000 patients internationally, and with strong eight-year patient
follow-up data. HYALOFAST is pending regulatory submission in the United
States and its FastTRACK Phase III trial is currently enrolling patients
across the U.S. and Europe.
“The ICRS Focus Meting in Milan is an excellent venue to further
showcase the significant advantages of our entire Orthobiologics
franchise before a collection of world-renowned experts in the field of
cartilage repair and regeneration,” said Joseph Darling, President
and CEO, Anika Therapeutics. “We believe that continuing this
peer-to-peer dialogue and technical training is central to further
advancing the HYALOFAST Phase III clinical trial, as well as increasing
commercial adoption. HYALOFAST is a truly remarkable advancement in the
treatment of cartilage injuries and defects due to its flexible
minimally-invasive means of application and adaptive fit to individual
HYALOFAST will be featured at the International Cartilage Regeneration
and Joint Preservation Society (ICRS) Focus Meeting in Milan, Italy
during a technical session. The meeting, which will be attended by many
of the world’s leading cartilage specialists, will showcase HYALOFAST as
part of its “RE-LIVE SURGERY SESSIONS” and its clinical data program.
HYALOFAST Technical SessionTitle: “Scaffolds: How to do It.
Re-live Surgery and Relevant Results”Presenter: Dr. Alberto Gobbi,
OASI Bioresearch Foundation, Milano – ItalyDate/Time: December 14,
2018 at 9:30 – 10:15am
Company-Sponsored BoothAnika will be a Gold Sponsor and
will host a booth (#12) featuring guest physicians leading guided,
hands-on demonstrations of HYALOFAST procedures using the HYALOFAST
Arthroscopic Virtual Surgery Simulator. The company will also host
“watch & try” sessions at the Anika booth.
About ICRSThe ICRS
(International Cartilage Regeneration and Preservation Society) is the
main forum for international collaboration in cartilaginous tissue
research that brings together basic scientists, clinical researchers,
physicians and members of industry, engaged or interested in the field
of articular biology, its genetic basis and regenerative medicine. It
provides continuing education and training to physicians and scientists
with an active interest in the prevention and treatment of joint disease
to improve patient care through regenerative medicine approaches.
2018 HYALOFAST Publications
Gobbi A., et al. Use of bone marrow aspirate concentrate
combined with hyaluronan-based scaffold for early osteoarthritis
in athletes. Football Medicine Outcomes Abstract book XXVII
Isokinetic Medical Group International Conference – Camp Nou,
Barcelona 2-4 June 2018. Ed Calzetti & Mariucci. Page 442.
Sofu H. et al. Clinical and radiographic outcomes of
chitosan-glycerol phosphate/blood implant are similar with
hyaluronic acid-based cell-free scaffold in the treatment of focal
osteochondral lesions of the knee joint. Knee Surg Sports
Traumatol Arthrosc. 2018 Aug 1. (Epub ahead of print).
Gollwitzer H. Operative Therapie – Knorpelschäden der Hϋfte
Einzeitiges arthroskopisches Verfahren zur Regeneration.
Sportärztezeitung 03/2018 (Cartilage Damage to the Hip. One-Stage
Arthroscopic Method of Regeneration).
About Anika Therapeutics, Inc.Anika
Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated
orthopedic medicines company based in Bedford, Massachusetts. Anika is
committed to improving the lives of patients with degenerative
orthopedic diseases and traumatic conditions with clinically meaningful
therapies along the continuum of care, from palliative pain management
to regenerative tissue repair. The Company has over two decades of
global expertise developing, manufacturing, and commercializing more
than 20 products based on its proprietary hyaluronic
acid (HA) technology. Anika’s orthopedic medicine portfolio
includes ORTHOVISC®, MONOVISC®,
which alleviate pain and restore joint function by replenishing depleted
HA, and HYALOFAST,
a solid HA-based scaffold to aid cartilage repair and regeneration. For
more information about Anika, please visit www.anikatherapeutics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181212005069/en/
Source: Anika Therapeutics, Inc.
For Investor Inquiries:Anika Therapeutics, Inc.Sylvia
Cheung, 781-457-9000Chief Financial Officer
For Media Inquiries:W2O GroupSonal Vasudev, 917-523-1418 firstname.lastname@example.org
Please visit their site for more information: Anika Therapeutics.com
All,Biotechnology,Healthcare News,Startup News